High-Grade Gliomas: Updates and Challenges
A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 86
Special Issue Editors
Interests: neuroprotection; apoptosis; nimodipine; calcium channel blocker; schwann cell; neuronal cell death; vestibular schwannoma; neurofibromatosis
Special Issue Information
Dear Colleagues,
Despite constant advances in medicine, high-grade gliomas are associated with an unfavourable prognosis. They represent a complex and challenging interdisciplinary field where the modern approach to imaging and therapy involves a multidisciplinary team of neurosurgeons, neurologists, neuroradiologists, and radiotherapists.
In recent years, advances in imaging, optimisation of radiation treatment plans, new developments in adjuvant drug therapy, and other intraoperative modalities such as intraoperative ultrasound have improved the overall diagnosis and management of this disease. The use of alternating electric fields (TTFields) as an adjunct therapy, the promising use of IDH-inhibiting drugs, and the trend of supramarginal resection, where safe, are also worthy of mention. In this Special Issue of Medicina, we aim to publish articles on further advances in high-grade gliomas in as broad a context as possible to provide readers with a comprehensive overview of the latest developments.
Comprehensive reviews, technical notes, opinions, and clinical and basic science research on high-grade gliomas are welcome in this Special Issue.
Dr. Sandra Leisz
Guest Editor
Dr. Maximilian Scheer
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- glioma
- glioblastoma
- neuro-oncology
- tumour biology
- imaging
- radiotherapy
- chemotherapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
